270 related articles for article (PubMed ID: 23547776)
1. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
[TBL] [Abstract][Full Text] [Related]
2. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Williams E; Bullock AN
Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
[TBL] [Abstract][Full Text] [Related]
4. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
6. BMP type I receptor inhibition reduces heterotopic [corrected] ossification.
Yu PB; Deng DY; Lai CS; Hong CC; Cuny GD; Bouxsein ML; Hong DW; McManus PM; Katagiri T; Sachidanandan C; Kamiya N; Fukuda T; Mishina Y; Peterson RT; Bloch KD
Nat Med; 2008 Dec; 14(12):1363-9. PubMed ID: 19029982
[TBL] [Abstract][Full Text] [Related]
7. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Engers DW; Frist AY; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2013 Jun; 23(11):3248-52. PubMed ID: 23639540
[TBL] [Abstract][Full Text] [Related]
10. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
[TBL] [Abstract][Full Text] [Related]
11. A new class of small molecule inhibitor of BMP signaling.
Sanvitale CE; Kerr G; Chaikuad A; Ramel MC; Mohedas AH; Reichert S; Wang Y; Triffitt JT; Cuny GD; Yu PB; Hill CS; Bullock AN
PLoS One; 2013; 8(4):e62721. PubMed ID: 23646137
[TBL] [Abstract][Full Text] [Related]
12. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
13. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy.
Shahid M; Spagnolli E; Ernande L; Thoonen R; Kolodziej SA; Leyton PA; Cheng J; Tainsh RE; Mayeur C; Rhee DK; Wu MX; Scherrer-Crosbie M; Buys ES; Zapol WM; Bloch KD; Bloch DB
Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H984-94. PubMed ID: 26873969
[TBL] [Abstract][Full Text] [Related]
14. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
[TBL] [Abstract][Full Text] [Related]
15. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
[TBL] [Abstract][Full Text] [Related]
16. Alk2/ACVR1 and Alk3/BMPR1A Provide Essential Function for Bone Morphogenetic Protein-Induced Retinal Angiogenesis.
Lee HW; Chong DC; Ola R; Dunworth WP; Meadows S; Ka J; Kaartinen VM; Qyang Y; Cleaver O; Bautch VL; Eichmann A; Jin SW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):657-663. PubMed ID: 28232325
[TBL] [Abstract][Full Text] [Related]
17. The specificities of small molecule inhibitors of the TGFß and BMP pathways.
Vogt J; Traynor R; Sapkota GP
Cell Signal; 2011 Nov; 23(11):1831-42. PubMed ID: 21740966
[TBL] [Abstract][Full Text] [Related]
18. BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma.
Strong AL; Spreadborough PJ; Dey D; Yang P; Li S; Lee A; Haskins RM; Grimm PD; Kumar R; Bradley MJ; Yu PB; Levi B; Davis TA
Stem Cells Dev; 2021 Jan; 30(2):91-105. PubMed ID: 33256557
[TBL] [Abstract][Full Text] [Related]
19. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
[TBL] [Abstract][Full Text] [Related]
20. Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H).
Sekimata K; Sato T; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Honma T; Tanaka A; Shirouzu M; Yokoyama S; Miyazono K; Hashizume Y; Koyama H
Chem Pharm Bull (Tokyo); 2019; 67(3):224-235. PubMed ID: 30828000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]